Tumor suppressor role of miR-503

Gupta, Gaurav; Dk, Chellappan; Pinto, Terezinha de Jesus Andreoli; Hansbro, Philip M.; Bebawy, Mary; Dua, Kamal

doi:10.23736/s0031-0808.17.03386-9

Cited by 62 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-503 was also found to be downregulated in GH-secreting adenomas [ 55 ]. This miRNA is also known as a tumor suppressor, as it is negatively correlated with different kinds of cancer, targeting IGF-1R , genes that are involved in the EMT, as well as fibroblast growth factor 2 ( FGF2 ), which plays a role in differentiation and proliferation [ 72 ].…”

Section: Mirnas In Acromegalymentioning

confidence: 99%

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands

Henriques

Lamback

Dezonne

et al. 2022

IJMS

View full text Add to dashboard Cite

Acromegaly is a chronic and systemic disease due to excessive growth hormone and insulin-like growth factor type I caused, in the vast majority of cases, by a GH-secreting pituitary adenoma. About 40% of these tumors have somatic mutations in the stimulatory G protein alpha-subunit 1 gene. The pathogenesis of the remaining tumors, however, is still not fully comprehended. Surgery is the first-line therapy for these tumors, and first-generation somatostatin receptor ligands (fg-SRL) are the most prescribed medications in patients who are not cured by surgery. MicroRNAs are small, non-coding RNAs that control the translation of many mRNAs, and are involved in the post-transcriptional regulation of gene expression. Differentially expressed miRNAs can explain differences in the pathogenesis of acromegaly and tumor resistance. In this review, we focus on the most validated miRNAs, which are mainly involved in acromegaly’s tumorigenesis and fg-SRL resistance, as well as in circulating miRNAs in acromegaly.

show abstract

Section: Mirnas In Acromegalymentioning

confidence: 99%

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands

Henriques

Lamback

Dezonne

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Treatments for liver cancer include chemotherapeutic, operation, and radiotherapy, but they have grim outcomes and long‐term side effects. In addition, migration, relapse, and drug resistance challenge liver cancer chemotherapy, as with other malignancies, prompting researchers to seek new treatments (Cheng et al, 2016; Gupta et al, 2017).…”

Section: Nutraceuticals Combating Lc Via Targeting the Nrf2/ho‐1 Sign...mentioning

confidence: 99%

The therapeutic role of nutraceuticals targeting the Nrf2/ HO ‐1 signaling pathway in liver cancer

Alharbi

Almalki

Albratty

et al. 2022

Journal of Food Biochemistry

Self Cite

View full text Add to dashboard Cite

Liver cancer (L.C.) is the most common cause of cancer death in the United States and the fifth most common globally. The overexpression of nuclear factor E2 related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) caused by oxidative stress has been associated with tumor growth, aggressiveness, treatment resistance, and poor prognosis. Nutraceuticals that inhibit Nrf2/HO-1 signaling may become the most effective strategy to treat liver cancer. Phytochemicals found in fruits and vegetables, also known as nutraceuticals, tend to emerge as chemopreventive agents, with the added benefit of low toxicity and high nutritional values. This paper reviews the present scientific knowledge of the Nrf2/HO-1 signaling as a possible target molecule for chemotherapeutic agents, its basic control mechanisms, and Nrf2/HO-1 inducers produced from natural products that might be employed as cancer chemopreventive drugs. The growing interest in the contribution of the Nrf2/ARE/HO-1 signaling in the development of liver cancer and the Use of nutraceuticals to treat liver cancer by targeting Nrf2/ARE/HO-1.

show abstract

“…miRNA-503 has been found to be highly expressed in ESCC and correlates with lymph node metastasis, TNM staging of the tumour (250) and poorer disease-free and overall survival (251). However, contrary to this, it has also been attributed to having tumour suppressor effects in ESCC (252)(253)(254) and other cell types (255). Similarly in gastric cancer, analysis of one thousand gastric cancer tissue samples showed miRNA-503 to be significantly upregulated (256), yet it has also been found to suppress GC cell growth and invasion (257) and EMT (258).…”

Section: Mirna-503mentioning

confidence: 99%

The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract

Ferris

2022

Front. Oncol.

View full text Add to dashboard Cite

Data from GLOBOCAN 2020 estimates that there were 19.3 million new cases of cancer and 10.0 million cancer-related deaths in 2020 and that this is predicted to increase by 47% in 2040. The combined burden of cancers of the gastrointestinal (GI) tract, including oesophageal-, gastric- and colorectal cancers, resulted in 22.6% of the cancer-related deaths in 2020 and 18.7% of new diagnosed cases. Understanding the aetiology of GI tract cancers should have a major impact on future therapies and lessen this substantial burden of disease. Many cancers of the GI tract have suppression of the tumour suppressor Programmed Cell Death 4 (PDCD4) and this has been linked to the expression of microRNAs which bind to the untranslated region of PDCD4 mRNA and either inhibit translation or target the mRNA for degradation. This review highlights the properties of PDCD4 and documents the evidence for the regulation of PDCD4 expression by microRNAs in cancers of the GI tract.

show abstract

Tumor suppressor role of miR-503

Cited by 62 publications

References 0 publications

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands

The therapeutic role of nutraceuticals targeting the Nrf2/ HO ‐1 signaling pathway in liver cancer

The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract

Contact Info

Product

Resources

About